Live · Research Wire
Life Biosciences / Harvard FDA clears Phase I trial of ER-100 — first-in-human partial cellular reprogramming for optic neuropathy (NAION, glaucoma); Q1 2026 dosing
Sinclair Lab · Patent Granted "Cellular reprogramming to reverse aging and promote organ and tissue regeneration" — over 50 cellular-reprogramming patents to date
Nature · Communications Biology Donor-specific trophoblast stem cells derived from chorionic villus biopsies — 2025 publication
Cell Stem Cell · 2017+ Foundational protocol for derivation of human trophoblast stem cells under defined conditions
MSC-EV Research Early-phase studies of MSC-derived extracellular vesicles report cartilage-repair signals in knee OA — endpoints, sample sizes and limitations in the trial record
Japan / MHLW Updated regenerative medicine framework (PMD Act tier-2 expansion) — Q1 2026 effective
European Medicines Agency ATMP fast-track expanded for exosome-based therapeutics
NIH / NIA $180M allocated to senolytic & peptide research, FY 2025–2028
Singapore A*STAR / IMB MSC-exosome glycolytic activity characterized — implications for scalable GMP manufacturing
Mayo Clinic Wearable biomarker monitoring + stem cell protocol Phase I clinical validation
UAE / Dubai Health First government-backed exosome therapy center launches in MENA region
Kyoto / CiRA (Yamanaka) iPSC-derived dopaminergic precursor cells advance through Parkinson's clinical trial
Life Biosciences / Harvard FDA clears Phase I trial of ER-100 — first-in-human partial cellular reprogramming for optic neuropathy (NAION, glaucoma); Q1 2026 dosing
Sinclair Lab · Patent Granted "Cellular reprogramming to reverse aging and promote organ and tissue regeneration" — over 50 cellular-reprogramming patents to date
Nature · Communications Biology Donor-specific trophoblast stem cells derived from chorionic villus biopsies — 2025 publication
Cell Stem Cell · 2017+ Foundational protocol for derivation of human trophoblast stem cells under defined conditions
MSC-EV Research Early-phase studies of MSC-derived extracellular vesicles report cartilage-repair signals in knee OA — endpoints, sample sizes and limitations in the trial record
Japan / MHLW Updated regenerative medicine framework (PMD Act tier-2 expansion) — Q1 2026 effective
European Medicines Agency ATMP fast-track expanded for exosome-based therapeutics
NIH / NIA $180M allocated to senolytic & peptide research, FY 2025–2028
Singapore A*STAR / IMB MSC-exosome glycolytic activity characterized — implications for scalable GMP manufacturing
Mayo Clinic Wearable biomarker monitoring + stem cell protocol Phase I clinical validation
UAE / Dubai Health First government-backed exosome therapy center launches in MENA region
Kyoto / CiRA (Yamanaka) iPSC-derived dopaminergic precursor cells advance through Parkinson's clinical trial
The Future of Regenerative Medicine

Where Biology
Meets Precision.
Where Science
Becomes Medicine.

Auvum Bio is the global platform uniting leading clinics, research institutions, and distribution partners around evidence-based regenerative therapies — stem cells, MSC-derived exosomes, human trophoblast stem cells, peptides, photobiomodulation, and the emerging OutPatient AI wearable program.

Q1'26
First-in-human cellular reprogramming dosing — Sinclair / Life Bio ER-100
240+
Active regenerative-medicine clinical trials worldwide (2011–2026)
$309B
Projected global exosome therapy market by 2035
85×
Population doublings achievable from a single hTSC line
Portrait of Dr. Robert Taylor, Co-Founder and Chief Medical Officer of Auvum Bio Co-FounderChief Medical Officer
Harvard M.D. & M.P.H. 40+ years clinical Boston's "Rock Doc" Bilingual · Bogotá
Chief Medical Officer

The person who decides
what Auvum will and will not
put its name on.

Dr. Robert Taylor M.D., M.P.H.

Co-Founder & Chief Medical Officer

Dr. Taylor sets the scientific standard for Auvum's work in stem cells, exosomes, and peptides, and leads the company's expansion into Bogotá — where speaking Spanish natively lets him build relationships with Latin American clinical and regulatory partners directly.

Four decades of practice sit behind that judgment: Harvard Medical School, the Harvard School of Public Health, residencies at Cambridge Hospital and the Boston VA, and more than thirty years as Boston's "Rock Doc" — the physician touring musicians call at 2 a.m.

“If the data would not survive a referee, Auvum does not put its name on it. That is the whole standard.”
Meet the full leadership team → ✉ Dr.taylor@auvum.bio
Lifetime of the Stem Cell

From fertilization
to year forty.

A single cell at conception holds the entire organism. Over the four decades that follow, potency narrows and plasticity drops — but new tools let us access, expand, and redeploy regenerative biology even in the adult body. Step through it, or drag the timeline.

Day 0 Phase I · Totipotency

Fertilization — two genomes become one.

Zygote · 1 cell · Totipotent

Two haploid gametes fuse into a single diploid cell — the only naturally totipotent cell a human ever has. It holds the instructions for every tissue, every organ, and the placenta that will sustain them. Everything that follows is a narrowing of that potential.
  • Diploid 2n
  • Totipotent
  • Maternal transcripts
REF · ScienceDirect ↗
Developmental potency100/100
Cell count1
Day 2 Phase I · Totipotency

Cleavage division.

2 · 4 · 8 cells · Totipotent

The zygote divides without growing — 2 cells, then 4, then 8, each smaller than the last. The embryo switches on its own genome around the 4-to-8-cell stage. Every blastomere here is still totipotent: isolate one, and it can build a whole organism.
  • Blastomeres 2→8
  • Genome activation
  • Totipotent
REF · NCBI Bookshelf ↗
Developmental potency98/100
Cell count2 → 8
Day 4 Phase I · Totipotency

Morula — compaction.

~16 cells · Totipotency closing

Sixteen cells compact into a solid mulberry-shaped ball, bound together by E-cadherin. Inside and outside cells now sit in different environments — the first hint of a decision. This is the last natural moment before lineage assignment begins.
  • Compaction
  • E-cadherin⁺
  • Pre-lineage
REF · PMC Stem Cells ↗
Developmental potency94/100
Cell count~16
Day 6 Phase II · Pluripotency

Blastocyst — the lineages split.

ICM (pluripotent) + TE (hTSC founder)

A fluid cavity opens and the embryo resolves into two founder populations. The Inner Cell Mass is pluripotent — it becomes the fetus, but cannot build placenta. The Trophectoderm becomes the placenta, and is the ancestor of every human Trophoblast Stem Cell: natively immune-privileged and genetically stable.
  • ICM · OCT4⁺ NANOG⁺ SOX2⁺
  • TE · CDX2⁺ GATA3⁺ TEAD4⁺
REF · Cell Stem Cell ↗REF · eLife ↗
Developmental potency86/100
Cell count~120
Day 9 Phase II · Pluripotency

Implantation — trophoblast commits.

Cytotrophoblast + syncytiotrophoblast

The blastocyst hatches from its shell and burrows into the uterine wall. Trophectoderm resolves into proliferative cytotrophoblast and the invading syncytiotrophoblast, which starts secreting hCG — the hormone a pregnancy test detects. This is where the trophoblast lineage commits to becoming placenta.
  • Zona hatching
  • CTB → STB fusion
  • hCG⁺
REF · Cell Stem Cell ↗REF · eLife ↗
Day 9 · implantation
Developmental potency80/100
Cell count~250
Wk 3 Phase II · Pluripotency

Gastrulation — three germ layers.

Endoderm · Mesoderm · Ectoderm

A primitive streak forms and pluripotent cells stream inward, folding into the three germ layers. Ectoderm becomes skin and nervous system; mesoderm becomes bone, muscle, blood and the MSC lineage; endoderm becomes gut, liver and lung. After this, the embryo's cells are committed to a layer — pluripotency is effectively spent.
  • Primitive streak
  • BRACHYURY⁺
  • Three germ layers
REF · NCBI Bookshelf ↗
Developmental potency74/100
Cell counttens of thousands
Wk 4 Phase II.5 · Trophoblast · hTSC Window

Chorionic villi form — hTSCs harvestable.

Weeks 4–12 · Auvum sourcing window · CD117⁺

The placenta grows chorionic villi — finger-like projections that hold the most accessible reservoir of human Trophoblast Stem Cells in the body. With informed consent, Auvum sources hTSCs from chorionic villus tissue donated after medical termination of clinically non-viable ectopic pregnancies (~2% of pregnancies globally). A single donation yields a renewable line capable of ~85× population doublings — on the order of 10²⁵ cells, enough for industrial-scale manufacture.
  • CDX2⁺
  • GATA3⁺
  • TEAD4⁺
  • ELF5⁺
  • CD117⁺
REF · Nature 2025 ↗REF · Cell Stem Cell ↗REF · PubMed ↗
Auvum focus
Developmental potency70/100
Cell count1 line → ~10²⁵
Wk 8 Phase III · Multipotency

Organogenesis and lineage commitment.

Weeks 4–8 · Tissue-specific stem cells

Organ primordia form and tissue-specific stem cells appear: hematopoietic stem cells in the fetal liver, mesenchymal stem cells in mesoderm, neural progenitors in the neural tube. By week 8 the embryo becomes a fetus with every organ system laid down. Potency has narrowed to multipotent — but each of these lineages now self-renews for life.
  • CD34⁺ HSC · fetal liver
  • MSC · mesoderm
  • Neural progenitors
REF · Nature STTT ↗
Developmental potency52/100
Cell count~10⁹
Birth Phase III · Multipotency

Cord blood and Wharton's jelly.

Day 0 of life · Neonatal HSC + MSC reservoir

Umbilical cord blood is dense with hematopoietic stem cells; Wharton's jelly holds young, highly proliferative mesenchymal stem cells. These are the most youthful multipotent cells naturally available after birth, and the starting material for many GMP-grade exosome programs. They are collected once, at delivery — or not at all.
  • CD34⁺ HSC
  • Wharton's jelly MSC
  • CD73⁺ CD90⁺ CD105⁺
REF · Nature CDD ↗
Developmental potency48/100
Cell count~2 trillion
Age 6 Phase III · Multipotency

Peak proliferation.

Years 1–12 · High-yield multipotent niches

Tissue-resident stem cell pools sit at their lifetime peak in both density and proliferative capacity. Bone marrow, dental pulp, adipose tissue and intestinal crypts all host vigorous niches. Wound healing and tissue turnover will never again be as fast as they are now.
  • Bone marrow
  • Dental pulp
  • Adipose
  • Gut crypt LGR5⁺
REF · PMC Retrospection ↗
Developmental potency42/100
Cell count~10 trillion
Yr 22 Phase IV · Adult Stem Cells

Adult stem cells stabilize.

Years 20–25 · BM-MSC · AD-MSC

Mesenchymal reservoirs in bone marrow and adipose tissue settle into steady maintenance and repair. Telomere length and methylation patterns are still favorable, and yields from a marrow or fat harvest are high. This is the ideal window for autologous banking.
  • Bone marrow MSC
  • Adipose-derived MSC
  • Telomere reserve
REF · Nature STTT ↗
Developmental potency32/100
Cell count~37 trillion
Yr 30 Phase IV · Adult Stem Cells

Senescence starts to accumulate.

Hayflick limit · Methylation drift

Stem cell function begins measurably declining. Senescent cells build up — they stop dividing but refuse to die, leaking inflammatory SASP signals into the surrounding tissue. Epigenetic methylation drifts away from its youthful pattern. Senolytic and peptide protocols become biologically meaningful here.
  • p16^INK4a⁺ senescence
  • SASP
  • Methylation drift
REF · PubMed · Sinclair ↗
Developmental potency26/100
Cell count~37 trillion
Yr 40 Phase IV · Adult Stem Cells

Extracted, expanded, redeployed.

Year 40 · The Auvum Inflection · Autologous therapy

At forty — and well beyond — viable adult stem cells remain accessible. Adipose tissue from liposuction and marrow from the iliac crest yield mesenchymal stem cells that can be expanded ex vivo, characterized, and reinfused, and their exosomes manufactured at GMP scale. Potency has fallen across four decades. Access has not — and that is the operational foundation of regenerative medicine.
  • Adipose-derived MSC
  • Bone marrow aspirate
  • Autologous
  • Exosome manufacture
REF · Nature STTT ↗
Auvum focus
Developmental potency18/100
Cell count~37 trillion

Stage 1 of 13 — Fertilization — two genomes become one.

← → to move · Home End to jump

Developmental potency across a lifetime

Potency falls. Access does not — and that is the whole argument.

FertilizationBirthYear 40
Methodology & data notes

Potency scores (0–100) are a qualitative index built for this visualisation, not a measured laboratory value. They rank developmental potential — totipotent (100) → pluripotent (~85) → multipotent (~50) → adult reservoir (~18) — so the decline can be read at a glance. They are not comparable across studies and should not be used as a specification.

Cell counts for embryonic stages are typical values from developmental-biology references; adult totals use the ~37 trillion figure from Bianconi et al. (2013). Individual variation is large.

Timeline spacing is deliberately non-linear. Days 0–12 weeks occupy roughly the first 45% of the rail and years 0–40 the remainder, so the embryonic stages stay legible. Read the rail as a sequence, not a scale.

Every stage links to its primary source. Where a claim is preclinical or in-vitro, the stage text says so. Nothing on this timeline should be read as a treatment claim: no hTSC- or exosome-derived product is FDA-approved for any indication.

The Auvum Platform

Five frontiers.
One integrated system.

01 / 05

Cellular Biologics

Mesenchymal stem cells (MSCs) and their nanoscale exosomes (30–150 nm) carry bioactive proteins, miRNA, and growth factors that mediate tissue repair and immune modulation — without the risks of live-cell transplantation. A paradigm shift now in Phase I and II trials globally.

MSC ExosomesCell-Free TherapyGMP-Grade
02 / 05

Human Trophoblast Stem Cells (hTSC)

A new class of immune-privileged, multipotent cells derived ethically from chorionic villi. Naturally genetically stable, capable of giving rise to all three germ layers, and demonstrating exceptional expansion (up to 85× population doublings). Highlighted below.

Immune PrivilegedThree Germ LayersHighly Scalable
03 / 05

Peptide & Senolytic Therapeutics

Targeted bioactive peptides modulate signaling pathways, accelerate tissue regeneration, and address cellular senescence — the biological hallmark of aging. Senolytic protocols selectively clear senescent cells driving chronic inflammation. NIH has committed $180M through 2028.

Bioactive PeptidesSenolyticsDNA RepairLongevity
04 / 05

Light & Pulse Technologies

Photobiomodulation (PBMT) at 630–940 nm activates cytochrome c oxidase in the mitochondrial respiratory chain, elevating ATP synthesis, reducing reactive oxygen species, and orchestrating regenerative signaling. A 2025 expert consensus confirmed PBM as safe and effective.

PBMT / Red LightNear-InfraredPEMFNon-Invasive
05 / 05

OutPatient AI · Wearable Program

In active development — and already being implemented with partner clinics. Continuous biomarker capture that continues after the study visit, so endpoints are measured rather than assumed.

Continuous BiomonitoringAI DosimetryTrial EnrollmentAny Device
See the programme
05 / 05 · OutPatient AI · Wearable Program

Regenerative medicine,
measured in real time.

The Auvum OutPatient AI program is in active development — a clinical-grade outpatient monitoring platform purpose-built to support clinics and clinical-trial sites. Fully customizable, designed to be compatible with virtually any smart health device, and engineered for both day-to-day care and rigorous trial enrollment workflows.

📊
Continuous biomarker monitoring
Real-time tracking of HRV, inflammatory proxies, sleep architecture, SpO₂, and cellular recovery indices — correlated directly with regenerative protocol timelines and dosing schedules.
🏥
Post-visit study monitoring
Research sites follow participants after a study visit with research-grade telemetry. Built for the OutPatient AI program — automated alerting, escalation, and documented follow-up.
🧪
Clinical trial enrollment & monitoring
Designed for trial-grade data capture: digital biomarkers, participant-reported outcomes, and automatic CRF population — making cohorts trackable across multi-site studies.
⚙️
Compatible with any device
Apple Watch, Oura, Whoop, Garmin, Polar, Dexcom CGM, blood-pressure cuffs, sleep mats — a unified ingest layer with fully customizable dashboards per clinic and per protocol.

We are implementing this with clinics now. Auvum works directly with partner research sites to stand OutPatient AI up alongside their existing study protocols — device onboarding, biomarker dashboards, and follow-up reporting configured around how the site already runs. If you want your site in the current cohort, ask.

✉ clinics@auvum.bio
In Development
Auvum OutPatient AI wearable
68
HRV ms · OutPatient AI
A Quantum Leap · Human Trophoblast Stem Cells

The earliest ethical source
of regenerative biology.

Human trophoblast stem cells (hTSCs) are derived from the trophectoderm — the outer cell layer of the early embryo that becomes the placenta — and are now being isolated and expanded under defined conditions in laboratories worldwide. They are natively immune-privileged, genetically stable, and possess an extraordinary expansion capacity that no other ethically-sourced human cell can match.

Unlike embryonic stem cells, hTSCs can be sourced without the destruction of viable embryos. They open a path to scalable, off-the-shelf cellular therapies for indications previously locked behind donor scarcity and immune compatibility.

Auvum's Mission

Auvum is engineering access to the
youngest ethically viable stem cell in the world.

Human Trophoblast Stem Cells, sourced from chorionic villi without harming any viable life, give clinical medicine its earliest and most potent regenerative starting material — a developmental window that no other ethically defensible cell source can match.

1Ethical Origin

hTSCs derived from chorionic villus tissue.

Auvum's hTSC lines are derived from chorionic villus tissue — the trophoblast-rich tissue of the developing placenta — collected during clinically indicated procedures, including the medical termination of non-viable ectopic pregnancies (roughly 2% of pregnancies globally, which require termination for maternal safety). Tissue is donated under written, IRB-approved informed consent, with no valuable consideration paid to the donor or the collecting facility. Every line carries donor-eligibility determination, infectious-disease screening, and full chain-of-custody documentation under 21 CFR 1271 Subpart C — available to qualified partners under NDA. One qualified donation seeds a master cell bank that supports years of research supply.

~2%
of pregnancies globally
1 line
every 1–2 months
2Cell Isolation

hTSCs isolated from chorionic villi, far from any non-viable fetus.

The chorionic villi — finger-like projections of the developing placenta — are the trophoblast tissue of origin. Recent work published in Nature Communications Biology (2025) and Cell Stem Cell demonstrates that donor-specific hTSC lines can be derived under defined media conditions from chorionic villus biopsies, reproducibly self-renewing while retaining differentiation competence.

85×
population doublings
10²⁵
cells from a single line

One stem cell. Many destinations.

Each lineage corresponds to a published induction protocol from the hTSC starting state — neural, pancreatic, hepatic, renal, immune-effector, mesenchymal, and exosome biomanufacturing pathways are all accessible from a single, scalable source. Hover any lineage to see lineage-specific markers and references.

Hover any lineage · 8 differentiation pathways
From a single hTSC — many destinations.
hTSCs natively perform functions of many cell types. Under defined induction conditions a single line is multipotent across endodermal, mesodermal, ectodermal, and trophoblast-derived lineages, while remaining genetically stable and immune-privileged.
CDX2⁺GATA3⁺TEAD4⁺ELF5⁺CD117⁺
Neural Progenitors
CNS · Peripheral nerve
SOX1⁺ PAX6⁺ NESTIN⁺
Pancreatic Progenitors
β-cell lineage
PDX1⁺ NKX6.1⁺ NEUROG3⁺
Hepatic Progenitors
Hepatocyte lineage
AFP⁺ HNF4α⁺ ALB⁺
Renal Progenitors
Nephron / tubule
SIX2⁺ WT1⁺ CITED1⁺
hTSC
Ethically sourced ·
Multipotent · Immune-privileged
iPSC Derivation
Pluripotent reprogramming
OCT4⁺ NANOG⁺ SOX2⁺
EVs & Exosomes
Cell-free secretome
CD9⁺ CD63⁺ CD81⁺
Effector Cells
NK / T-cell lineage
CD3⁺ NKG2D⁺ GZMB⁺
Mesenchymal Lineages
Bone · cartilage · adipose
CD73⁺ CD90⁺ CD105⁺
The Auvum Platform · Multi-Modal Capabilities

Three modalities. One integrated standard.

Auvum partners gain access to human Trophoblast Stem Cells (hTSC), Mesenchymal Stem Cells (MSC) — including youthful umbilical-cord (Wharton's jelly) MSCs — and cGMP-grade therapeutic peptides, all manufactured to the same regulatory standard and supported by a unified protocol stack.

Across cellular therapies (hTSC + MSC) and cGMP peptide therapeutics, strict adherence to cGMP and CMC is non-negotiable — even minor deviations impact identity, potency, and reproducibility.

Auvum upholds current Good Manufacturing Practice (cGMP) and Chemistry, Manufacturing & Controls (CMC) standards across every cell line and every peptide API we work with. Starting-material qualification, identity testing, sterility assurance, potency assays, residual-host-cell impurity profiling, and tightly controlled differentiation and synthesis protocols are the non-negotiable foundations of safe, effective therapy — for cells and small molecules alike.

⊙

Core IP, Protocols & Process Design

Partners receive validated process designs and core intellectual property across our hTSC and MSC cell programs and our cGMP peptide library — accelerating any program from day one.

✓

De-Risked cGMP Starting Material

We solve the starting-material problem on your behalf — qualified hTSC and MSC master cell banks plus cGMP peptide APIs with full CoA — so your team focuses on the research, not on sourcing raw materials.

⌬

Multi-Modal Bioplatform

Auvum is building a platform that lets every partner leverage best-in-class hTSC and umbilical-cord MSC sources alongside our cGMP peptide pipeline — with shared standards, cross-modality reproducibility, and a single regulatory dossier framework.

⚗

Cost & Time Reduction

We reduce development and commercialization costs across cell-therapy programs and peptide programs alike — so partners can run more programmes, and run them further, on the same budget.

Nature Communications Biology · 2025 Cell Stem Cell · Derivation of hTSCs eLife · TSCs from Naïve hPSCs PMC · Induced TSC-like Cells PNAS · TSC Induction Nature Communications · 2023 Cell Mol Life Sci · Springer Nature PMC · Accessing the hTSC State PubMed · hTSC in Sepsis Models
Stem Cell Comparison

A taxonomy of regenerative tools.

Different cell sources answer different clinical questions. The Auvum platform standardizes the comparison so practitioners can match biology to indication with rigor.

Filter the taxonomy

Showing 8 of 8
Cell / Vesicle SourceOriginPotencyImmunogenicityRegenerative CapacityBest Use CasesEvidence
Human Trophoblast SC (hTSC)
Chorionic villi · ectopic donations
Trophectoderm of early embryoMultipotent (broad)PrivilegedPancreatic, hepatic, renal, neural, NK/T-cell, MSC, exosome biomanufactureNature 2025Cell Stem Cell
Embryonic Stem Cells (ESCs)
Inner cell mass · blastocyst
Donated embryos (IVF surplus)PluripotentHigh riskResearch models, tissue engineering scaffoldsFrontiers
Induced Pluripotent SCs (iPSCs)
Yamanaka factors · OSKM
Reprogrammed adult fibroblastsPluripotentVariableCell replacement, drug discovery, Parkinson's, retinal diseasePubMed
Hematopoietic Stem Cells (HSCs)
Bone marrow · cord blood
Marrow, peripheral blood, cord bloodMultipotentModerateLeukemia, lymphoma, immune reconstitution (FDA-approved)Nature 2025
Mesenchymal Stem Cells (MSCs)
Marrow · adipose · Wharton's
Bone marrow, adipose tissue, umbilical cordMultipotentLowJoint repair, GVHD, autoimmune, wound healingNature CDD
MSC-Derived Exosomes
30–150 nm · cell-free
Conditioned media of MSCsN/A (vesicle)MinimalCartilage, neurological, cardiac, anti-inflammatoryFrontiers '26
Adipose-Derived SCs (ADSCs)
SVF · liposuction-derived
Subcutaneous fat (autologous)MultipotentVery lowOrthopedic, cosmetic, soft-tissue regenerationPMC
Platelet-Rich Plasma (PRP)
Concentrated platelets
Donor's own peripheral bloodGrowth factors onlyNone (auto.)Tendinopathy, hair restoration, dermatologyPMC

Comparison adapted from peer-reviewed sources cited above. Regenerative-capacity scoring is qualitative and clinical-context-dependent.

Methodology & data notes

Regenerative-capacity bars are qualitative — a five-point editorial score synthesised from the cited reviews, not a measured value, and not comparable between rows as a ratio. Read them as "how broadly is this source being investigated", not "how well does it work".

Immunogenicity describes the expected host response for an allogeneic product of that class; an autologous preparation of the same cell type behaves differently. "Has an approved use" means the class has at least one approved indication in at least one major market — it does not mean the row is approved for the use cases listed beside it.

Of the sources listed, only hematopoietic stem cell transplantation and platelet-rich plasma have established regulatory pathways in the United States for the uses shown. hTSC, MSC-exosome, and iPSC products are investigational.

Peptide Therapeutic Landscape

Targeted peptides for
longevity, repair, and resilience.

A growing class of small bioactive peptides target precise pathways: telomere maintenance, DNA-damage response, neurorepair, and immune calibration. Evidence quality varies; Auvum tracks the data — and where it falls short — transparently.

DNA double helix mid-repair with PARP / Ku70/80 repair complex
DNADouble-Strand Break Repair · PARP · Ku70/80

Search the peptide library

Showing 9 of 9
PeptidePrimary TargetLongevityDNA RepairNeuroImmuneEvidence StatusReferences
Epitalon (Epithalon)
Ala-Glu-Asp-Gly · pineal
Telomerase activatorHighHighModModRussian gerontology data on telomere extension; limited Western RCTs.Frontiers '26
Thymosin α-1
Thymic peptide
T-cell maturation · innate immunityModLowLowHighTα-1 approved in 35+ countries (Zadaxin) for hepatitis & immune indications.PMC '20
BPC-157
Body Protection Compound
Angiogenesis · gut & tendon repairLowModModModStrong animal data; human safety/dosing not fully characterized.PMC Review
GHK-Cu
Gly-His-Lys Copper
DNA damage response · skin remodelingModHighModModModulates ~4,000 genes; topical use established.PMC
Cerebrolysin
Porcine neuropeptide
Neurotrophic · BDNF / NGF mimeticLowLowHighLowApproved in 50+ countries for stroke recovery, dementia, TBI.Frontiers '26
Semax / Selank
ACTH-derived neuropeptides
BDNF upregulation · anxiolyticLowLowHighModRussian clinical use for cognitive impairment, stroke. No US approval.PMC
TB-500 (Thymosin β-4 frag.)
Actin-binding peptide
Cell migration · wound healingLowModModModAnimal studies favorable; FDA flagged purity concerns.PMC Sports
NAD⁺ Precursors (NMN/NR)
Nicotinamide derivatives
Sirtuin activation · mitochondriaHighHighModModMultiple human RCTs (Sinclair lab et al.); biomarker improvements.PubMed
Senolytic Stack (D+Q, Fisetin)
Dasatinib + Quercetin · Fisetin
Selective senescent-cell clearanceHighModModHighMayo Clinic Phase II IPF & diabetic kidney disease; NIH-funded.PMC

Auvum publishes evidence transparently. "High / Mod / Low" reflects current peer-reviewed support, not regulatory approval. Several peptides above are not FDA-approved for the indications shown and remain investigational.

Methodology & data notes

"High / Mod / Low" is an evidence-strength score, not an efficacy score and not a regulatory status. It reflects how much peer-reviewed human and animal data currently supports activity in that domain. A "High" in one column and no approval anywhere are entirely consistent.

Several peptides listed are not approved by the FDA for any indication and have no lawful compounding route in the United States. Where a peptide is approved, the approving jurisdiction is named in the Evidence Status column. Availability differs by market — ask before assuming.

Where evidence rests on animal models or on clinical use outside Western regulatory review, the Evidence Status column says so explicitly. Auvum publishes the gaps as well as the support.

Global Research at the Frontier

The world's most ambitious
cellular research — in one place.

Auvum tracks and indexes leading regenerative-medicine research worldwide. Beyond the Sinclair / Life Bio program featured above, here are flagship laboratories whose work informs and shapes our protocols.

Kyoto · Asia-Pacific
Center for iPS Cell Research and Application (CiRA), Kyoto University — Founded by Nobel laureate Prof. Shinya Yamanaka
iPSC-derived dopaminergic neurons in Parkinson's disease.
CiRA's clinical program transplants iPSC-derived dopaminergic precursors into the putamen of trial participants with Parkinson's disease. Phase I/II reported safe motor improvement; Phase II underway through 2026.
PubMed eLife
Singapore · A*STAR
Institute of Medical Biology (IMB), A*STAR — Prof. Sai-Kiang Lim, pioneer of MSC-exosome therapy
Foundational MSC-exosome characterization.
Lim's group first demonstrated that the cardioprotective effect of MSCs was carried by their secreted exosomes — establishing the entire field of cell-free regenerative therapy. Recent A*STAR work characterizes glycolytic activity and scalable manufacturing.
Springer Nature Nature CDD
Stockholm · EU
Karolinska Institutet · Department of Laboratory Medicine
MSC-EVs for graft-versus-host disease.
Karolinska researchers pioneered compassionate-use MSC-derived extracellular vesicle therapy in steroid-refractory GVHD — establishing the first clinical evidence base for cell-free vesicular biologics in immune disease.
Nature CDD
USA · Rochester
Mayo Clinic · Robert and Arlene Kogod Center on Aging
Senolytic D+Q clinical translation.
Mayo has carried senolytic Dasatinib + Quercetin from mouse to humans, with completed Phase II studies in idiopathic pulmonary fibrosis and diabetic kidney disease. NIH-funded; the benchmark for senolytic translation.
PMC
China · Frontiers '26
Multi-institution consortia · Frontiers in Pharmacology, May 2026
MSC-exosomes in myocardial infarction repair.
Scaffold-based delivery of MSC-derived exosomes is improving angiogenesis, suppressing apoptosis, and modulating inflammation post-MI — translating animal cardiac repair into early-stage human protocols.
Frontiers '26
EU · Gerontology
Frontiers in Aging — peptide gerontology consortium, 2026
Therapeutic peptides for healthy aging.
Comprehensive 2026 review of mechanisms and applications of peptide therapeutics in healthy aging — covering Epitalon, Thymalin, Cerebrolysin, GHK-Cu, and emerging mitochondrial peptides; risks and unknowns examined.
Frontiers '26
USA · Nature
Nature Communications Biology · 2025
Donor-specific hTSCs from chorionic villi.
Demonstrates derivation of donor-specific human trophoblast stem cells from clinically available chorionic villus biopsies — establishing a reproducible, scalable, ethically-sound entry point for hTSC-based therapies.
Nature 2025
Translational Medicine
Multi-institution · Nature STTT, 2025
MSCs in human disease — comprehensive review.
Nature Signal Transduction and Targeted Therapy 2025: a definitive synthesis of mesenchymal stem cell mechanisms and clinical applications across orthopedic, neurologic, immune, and metabolic diseases.
Nature 2025
Inside the Vesicle

What is actually in an exosome?

"Proteins, miRNA, and growth factors" is where most explanations stop. Here are the molecules, what they do in the recipient cell, and how strong the evidence is for each. Select a cargo class.

miRNA TSG-6 · IDO VEGF · HGF ESCRT 30–150 nm · CELL-FREE
Surface identity

Tetraspanins

CD9 · CD63 · CD81 · CD82

These four-pass membrane proteins stud the vesicle surface and are the standard identity markers used to confirm that a preparation actually contains exosomes rather than apoptotic debris or protein aggregates. MISEV2023 guidance requires at least one tetraspanin plus one cytosolic marker before a preparation may be called an EV product. They also mediate the first contact between vesicle and recipient cell.

CD9CD63CD81CD82Integrins α4/β1
Evidence tier · Identity marker

Characterization, not a therapeutic claim. This is what a certificate of analysis must show.

Methodology & data notes

Cargo classes and marker sets follow MISEV2023 (Minimal Information for Studies of Extracellular Vesicles), the field's consensus characterization standard. Evidence tiers on each panel describe the strength of evidence for that cargo's mechanism, not for any product.

Vesicle content varies with donor, tissue source, passage number, and culture conditions. Two MSC-exosome preparations are not interchangeable without comparative potency data. No exosome product is FDA-approved for any indication, and the FDA has issued warning letters and a public safety notification concerning unapproved exosome products.

Cryo-electron microscopy of MSC-derived exosomes
MSC-Derived Exosome — 30–150 nm Carries therapeutic miRNA, growth factors, and bioactive proteins across biological barriers with minimal immunogenicity.
The Mechanism

Not a promise.
A mechanism.

Every Auvum protocol is built on peer-reviewed mechanisms of action — validated pathways of cellular communication, bioenergetics, and regeneration. We do not pursue trends. We pursue biological truth.

Intercellular signaling at nanoscale
Exosomes deliver bioactive cargo — miRNA, proteins, lipids — that reprogram target cells toward regenerative phenotypes, reducing inflammation and stimulating endogenous repair without the risks of live-cell transplantation.
Mitochondrial bioenergetic activation
PBMT at 630–940 nm activates cytochrome c oxidase in the mitochondrial respiratory chain, increasing ATP synthesis and modulating reactive oxygen species — measurable within hours of a single session.
Senescence clearance and tissue renewal
Senolytic peptide protocols selectively eliminate senescent cells driving chronic inflammation and tissue dysfunction — a key biological driver of age-related decline, metabolic disease, and impaired recovery.
Research Landscape 2026

The science is
accelerating rapidly.

$58B
Global exosome therapy market valuation
$309.6B projected by 2035 · CAGR 18.2%
240+
Registered exosome clinical trials globally, 2011–2026
21% direct therapeutic application
85×
Population doublings achievable from a single hTSC line
~10²⁵ cells from one donation
Q1 '26
First-in-human cellular reprogramming trial dosing
Life Biosciences ER-100 · FDA-cleared
Who We Serve

Built for the
builders of what's next.

Whether you operate a world-class clinic, conduct the research that defines tomorrow's protocols, or distribute medical innovations — Auvum was architected for you. Our founding-stage focus is on connecting research labs with clinical sites across four anchor markets.

★ United States ★ India ★ Colombia · LATAM anchor ★ Philippines · ASEAN gateway

Which Auvum relationship fits you?

Four questions. We will tell you which track you belong in, what we will need from you, and — just as usefully — what we cannot supply in your jurisdiction.

Question 1 of 4
What kind of organisation are you?
Where will the work happen?
What regulatory cover do you already have in place?
What are you looking for first?

Elevate your clinic to the frontier

Auvum partners with forward-thinking clinics across our priority markets — the United States, India, the Philippines, and Colombia, our anchor for Latin America — to deploy evidence-based regenerative protocols. Approved clinics sign up once and gain direct product access through our partner labs and research institutions — hTSC and MSC cell programs, MSC-derived exosomes, cGMP peptides, and clinical hardware — with comprehensive training, regulatory navigation, and OutPatient AI integration that turns outcomes into measurable data. Colombia's world-class medical sector serves as our entry point to the broader LATAM region.

  • Direct product access sourced from Auvum partner labs and research institutions — no third-party intermediaries
  • GMP-grade MSC-derived exosomes, MSC and hTSC cell programs, and the Auvum cGMP peptide library
  • Turnkey photobiomodulation (PBMT) and PEMF protocol systems
  • OutPatient AI integration for real-time study outcome monitoring
  • Ongoing clinical education, protocol updates, and peer network
  • Multi-language study documentation and consent materials (12+ languages)
  • Regulatory compliance guidance across 40+ jurisdictions
Founding Clinic Network · Now Onboarding
Network Stage
Founding Cohort
Open · Apply Now
Combined Addressable Population
2.5B+
4 priority regions
Strategic Markets · Auvum Priority Index
United States · 335M · regen-med leader★★★★★
India · 1.43B · biotech hub★★★★★
Colombia · world-class medical sector · LATAM anchor★★★★★
Philippines · 115M · ASEAN gateway★★★★☆
Indicators reflect strategic prioritization, not current operational scale. Auvum is in its founding-partner phase.

Accelerate discovery with Auvum

Auvum's mission is to connect research labs with the clinical centers that can carry their work into registered studies. We partner with universities and institutes — in the US, India, the Philippines, and across Latin America (anchored by Colombia) — to share standardized biologics, hTSC starting material, protocol infrastructure, and a growing network of clinical sites. The result: translational research moves from lab bench to validated protocol to widespread adoption, faster than any single institution could alone.

  • Standardized research-grade exosome, MSC, and hTSC supply with CoA documentation
  • Multi-site clinical network access for accelerated trial recruitment
  • OutPatient AI longitudinal biomarker outcome tracking
  • Joint publication and IP framework agreements
  • Auvum Research Grant Program — annual cycle, open applications
  • Priority access to proprietary Auvum clinical outcome datasets
Research Footprint Priorities
Cohort Stage
Open · Founding
Applications welcome
Research Grant Program
Annual Cycle
5 indication areas
Target Research Regions · Priority Index
United States · Harvard / Stanford / Mayo★★★★★
India · AIIMS / IISc / IITs★★★★★
Colombia · UniAndes / UdeA / UNAL · LATAM anchor★★★★★
Philippines · UP Manila / PGH★★★★☆
Indicators reflect strategic prioritization. Auvum is actively recruiting principal investigators across these regions.

Distribute the future of medicine

Auvum is appointing founding distribution partners across four priority regions: the United States, India, the Philippines, and Latin America — where Colombia is our anchor market. Colombia's INVIMA-regulated medical sector is one of the most advanced in Latin America and a strategic gateway to the broader region. We bring validated regenerative biologics and technologies with full cold-chain logistics, regulatory dossier support, and in-country clinical infrastructure — and we connect distribution partners directly with the research labs and clinical sites that anchor each market.

  • Exclusive or co-exclusive territory arrangements available
  • Full regulatory filing support and dossiers per jurisdiction
  • Cold-chain certified biologics distribution infrastructure
  • Technical training and clinical champion network
  • Marketing and clinical materials in 12+ languages
  • Dedicated Auvum partner account management and co-marketing
Market Opportunity by Region
Onboarding Status
Founding Cohort
Multi-region · Open
Regen-Med Market Trajectory
$58B → $309B
CAGR ~18% to 2035
Target Distribution Markets · Opportunity Index
USA · 335M · FDA pathway★★★★★
India · 1.43B · CDSCO active★★★★★
Colombia · INVIMA · gateway to LATAM★★★★★
Philippines · 115M · FDA-PH · ASEAN hub★★★★☆
Indicators reflect addressable market potential, not Auvum's current distribution. We are actively appointing founding distribution partners.
Scientific Evidence Base

The world's leading
institutions inform our science.

Auvum protocols are built on peer-reviewed research from the most respected biomedical institutions globally. We translate evidence into clinical practice — rigorously, responsibly, and at scale.

Research institutions listed are cited within Auvum's published scientific evidence base. Partnership and collaboration status varies by institution.

Every Source on This Page

The evidence index.

Every citation anywhere on this page, collected in one place and built at load time from the page itself — so it can never drift out of date. Search it, filter it, and jump straight to where each one is used.

Citation index

Building…

These are sources, not sponsors. Citation of a journal, institution, or trial does not imply any partnership with, sponsorship by, or endorsement of Auvum Bio.

The Vision
"For the first time in the history of medicine, a drug candidate based on partial cellular reprogramming is entering human clinical trials. We are testing whether the aging process itself can be safely modified."
Prof. David A. Sinclair, PhD · Life BiosciencesOn FDA IND clearance for ER-100, 2026
Join the Auvum Network

This is where the
future of medicine
is being built.

Join the clinics, distribution partners, and research institutions defining the next chapter of human health. Applications are reviewed on a rolling basis by our partnership team.

🏥

Clinics

Sign up once for direct product access through Auvum's partner labs and research institutions — plus OutPatient AI outcome monitoring.

🔬

Research Partners

Access standardized biologics, hTSC starting material, and the Auvum Research Grant Program.

🌐

Distribution Partners

Bring Auvum's validated regenerative biologics and technologies to your market.

✉️

General Inquiry

Investors, press, prospective team members, or anyone exploring a relationship with Auvum — start the conversation here.

Global Presence

Headquarters across
four continents.

Auvum operates regional headquarters in the United States and Colombia, with offices in India and the Philippines opening soon. We are already actively engaged in every one of these markets — building relationships with clinics, institutions, and agencies.

Austin, USA
🇺🇸
Global Headquarters
Operational

1005 Congress Avenue, Suite 925
Austin, TX 78701, United States

Tel+1 512 541 2026
Fax+1 512 541 2025
Bogotá, Colombia
🇨🇴
Latin America Headquarters
Operational

Calle 90 # 11-13, Piso 5
Complejo Urban Plaza, Bogotá, Colombia

Tel+57 601 916 3243
Fax+57 601 916 3243
Direct dial: 601 916-3AGE
New Delhi, India
🇮🇳
South Asia Office
Opening Late 2026 · Early 2027

Auvum is establishing its South Asia base in New Delhi. We are already actively working with clinics, institutions, and agencies across India ahead of the office opening.

Manila, Philippines
🇵🇭
ASEAN Gateway Office
Opening Late 2026 · Early 2027

Manila will serve as Auvum's gateway to the ASEAN region. Partnerships with clinics, institutions, and agencies across the Philippines are already underway ahead of opening.

Across all four markets, Auvum is already actively working with clinics, institutions, and agencies — laying the groundwork today for the regenerative-medicine network of tomorrow.